Halozyme Therapeutics, Inc. (HALO) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-06
(Q2 2026)
— full calendar
Earnings Reports
-
Halozyme (HALO) Q1 2026: Royalty Revenue Up 43% as Enhanced Pipeline Sets Up 13 New Launches
May 12, 2026
-
Halozyme (HALO) Q4 2025: Royalty Revenue Surges 52% as Hyperconcentration Platform Expands IP Runway
January 30, 2026
-
Halozyme (HALO) Q2 2026: Royalty Revenue Surges 52% as HyperCon and SurfBio Expand IP Runway
January 28, 2026
-
HALO (HALO) Q3 2025: Royalty Revenue Surges 52% as Subcutaneous Therapies Expand Market Reach
November 04, 2025
-
Halozyme (HALO) Q2 2025: Royalty Revenue Surges 65%, Accelerating Durable Platform Leverage
August 06, 2025
-
Halozyme (HALO) Q1 2025: Royalty Revenue Jumps 39% as Eleven Growth Catalysts Activate
July 06, 2025